title: Efficacy and Safety of Bortezomib in Multiple Myeloma Patients with Hepatitis B: A Multicenter Retrospective Study.
abstract: BACKGROUND
  The efficacy and safety evidence of bortezomib in multiple myeloma (MM) patients with hepatitis B is vacant. This study aimed to investigate the efficacy and safety of bortezomib in MM patients with hepatitis B in China.
  
  
  METHODS
  From 2006 to 2011, 739 newly diagnosed MM patients were screened for serum hepatitis B virus (HBV) biomarkers. HBV-infected patients were followed for HBV reactivation by monitoring of serum alanine transaminase (ALT) and HBV DNA load. The pattern of HBV reactivation in relation to bortezomib was evaluated. Seven hundred thirty-nine MM patients were included in this study.
  
  
  RESULTS
  The prevalence of MM patients infected with HBV was 3.4% (n = 25), of which 17 cases were treated with bortezomib. Bortezomib had no significant influence on liver function (ALT before and after treatment: 36.69 ± 8.90 U/L vs. 11.31 ± 2.74 U/L, P = 0.19) and HBV DNA of MM patients with HBV (detectable HBV DNA percentage: 5.9% vs. 11.8%, P = 0.12).
  
  
  CONCLUSIONS
  Bortezomib can be used safely and effectively in MM patients with hepatitis B. HBV prophylaxis and surveillance are recommended during the MM treatment.
authors.forename: Jin
authors.initials: J
authors.lastname: Lu
authors.forename: Wen-Ming
authors.initials: WM
authors.lastname: Chen
authors.forename: Chuan-Ying
authors.initials: CY
authors.lastname: Geng
authors.forename: Brian Gm
authors.initials: BG
authors.lastname: Durie
authors.affiliation: Department of Hematology, Peking University People's Hospital and Peking University Institute of Hematology, Beijing 100044, China.
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Huang
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D000069286:Bortezomib / Q000627:therapeutic use*; D004279:DNA, Viral / Q000187:drug effects / Q000235:genetics; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy* / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects / Q000472:pathogenicity; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000821:virology; D012189:Retrospective Studies; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D000069286:Bortezomib
references.citation: Int J Hematol. 2010 Jun;91(5):844-9
references.pmid: 20473594
references.citation: J Virol Methods. 2008 Jul;151(1):95-100
references.pmid: 18455810
references.citation: J Virol. 2000 Feb;74(3):1393-406
references.pmid: 10627550
references.citation: N Engl J Med. 2003 Jun 26;348(26):2609-17
references.pmid: 12826635
references.citation: J Virol. 2005 Jan;79(1):644-8
references.pmid: 15596861
references.citation: Arch Intern Med. 2005 Feb 28;165(4):464-5
references.pmid: 15738379
references.citation: PLoS One. 2008;3(7):e2585
references.pmid: 18612413
references.citation: J Clin Oncol. 2008 Oct 10;26(29):4784-90
references.pmid: 18711175
references.citation: J Virol. 2009 Mar;83(6):2469-79
references.pmid: 19129442
references.citation: Vaccine. 2009 Nov 5;27(47):6550-7
references.pmid: 19729084
references.citation: Antimicrob Agents Chemother. 2010 Feb;54(2):749-56
references.pmid: 19949053
references.citation: Expert Rev Anti Infect Ther. 2005 Feb;3(1):61-79
references.pmid: 15757458
references.citation: Br J Haematol. 2005 Jun;129(6):755-62
references.pmid: 15953001
references.citation: Br J Haematol. 2005 Jun;129(6):776-83
references.pmid: 15953004
references.citation: Antivir Ther. 2006;11(8):995-1004
references.pmid: 17302369
references.citation: Lancet Oncol. 2010 Sep;11(9):827-34
references.pmid: 20688564
references.citation: Turk J Gastroenterol. 2010 Jun;21(2):197-8
references.pmid: 20872342
references.citation: Ann Oncol. 2012 Feb;23(2):421-6
references.pmid: 21551005
references.citation: Am J Pathol. 2003 Aug;163(2):381-5
references.pmid: 12875959
references.citation: Blood. 2007 Apr 1;109(7):2767-72
references.pmid: 17148584
references.citation: Br J Haematol. 2007 Aug;138(3):330-7
references.pmid: 17614819
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3892-901
references.pmid: 17679727
references.citation: Blood. 2008 Mar 1;111(5):2516-20
references.pmid: 17975015
references.citation: J Virol. 2010 Aug;84(15):7880-5
references.pmid: 20484516